Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

Next Previous
Search
Trial Profile

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms TURQUOISE-III
  • Sponsors AbbVie

    • Most Recent Events

    • 07 Mar 2018 Results of pooled data from nine clinical trials, were published in the Clinical Pharmacokinetics.
    • 23 May 2016 Time frame of the primary end point changed from 12 weeks after the last actual dose of study drug to Post-treatment Day 1 to Post-treatment Week 12.
    • 25 Apr 2016 According to a Enanta Pharmaceuticals media release, the US FDA approved its supplemental NDA for the use of VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir tablets) + dasabuvir tablets without ribavirin in patients with genotype 1b (GT1b) chronic hepatitis C virus infection and compensated cirrhosis (Child-Pugh A), based on the results of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top